Prospects for gene therapy in Parkinson's disease.

Publication Type	Review
Authors	Freese A, Stern M, Kaplitt M, O'Connor W, Abbey M, O'Connor M, During M
Journal	Mov Disord
Volume	11
Issue	5
Pagination	469-88
Date Published	09/01/1996
ISSN	0885-3185
Keywords	Genetic Therapy, Parkinson Disease
Abstract	Numerous advances in in vivo and ex vivo gene-therapy approaches to Parkinson's disease offer promise for direct clinical trials in patients in the next several years. These systems are predicated on introducing gene that encode enzymes responsible for dopamine biosynthesis or neurotrophic factors that may delay nigrostriatal degeneration or facilitate regeneration. We review the current status of experimental approaches to gene therapy for Parkinson's disease. Comparative advantages and disadvantages of each system are enumerated, and preclinical trials of some of the systems are evaluated. Although the specific in vivo or ex vivo methods used for gene transfer into the brain are likely to be supplanted by newer technology over the next decade, the principles and approaches developed in current studies likely will remain the same.
DOI	10.1002/mds.870110502
PubMed ID	8866488